Inrebic, a once-daily oral capsule, is the second treatment approved in the U.S. for myelofibrosis. The drug is manufactured by Impact Biomedicines, a subsidiary of Celgene.
The drug, a kinase inhibitor, targets treatment-naive myelofibrosis, a bone marrow disorder that disrupts the normal production of blood cells.
The approval is the first new treatment for the disease in nearly a decade.
It also comes as a win for drug giant Bristol-Myers Squibb, which is finalizing its merger with Celgene.
More articles on pharmacy:
CMS to cover CAR-T therapy nationwide
Colombia fines Pfizer $25K for drug price inflation
Jefferson Healthcare opens retail specialty pharmacy
